Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.

Literature DB >> 3163908

In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.

Abstract

The activity of cefotetan against 430 strains of anaerobic bacteria was compared with that of cefoxitin, ceftizoxime, clindamycin, metronidazole, and chloramphenicol. Percent susceptible values for the Bacteroides fragilis group were 60, 80, 29, 86, 100, and 100%, respectively. Percent susceptible values for the B. fragilis species were 91, 92, 46, 98, 100, and 100%, respectively. Non-B. fragilis-group Bacteroides species were inhibited very well (90 to 100%) by all drugs except ceftizoxime (80%). Cefotetan and metronidazole were the most active agents against Clostridium difficile. Percent susceptible values for all strains were 72, 79, 44, 82, 93, and 98%, respectively.

Entities: Chemical Species

Mesh：

Substances：

Year: 1988 PMID： 3163908 PMCID： PMC172231 DOI： 10.1128/AAC.32.4.601

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

Review 1. Antimicrobial resistance in Bacteroides.

Authors: H M Wexler; S M Finegold
Journal: J Antimicrob Chemother Date: 1987-02 Impact factor: 5.790

2. Pharmacokinetics of ceftizoxime.

Authors: R E Cutler; A D Blair; E D Burgess; D Parks
Journal: J Antimicrob Chemother Date: 1982-11 Impact factor: 5.790

3. Activity in vitro of cefotetan against non-sporing anaerobes: a comparative study.

Authors: G Ruckdeschel
Journal: J Antimicrob Chemother Date: 1983-01 Impact factor: 5.790

4. Inhibitory activity of cefotetan and other beta-lactams against anaerobes.

Authors: H Werner
Journal: J Antimicrob Chemother Date: 1983-01 Impact factor: 5.790

5. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers.

Authors: J Guibert; M D Kitzis; C Yvelin; J F Acar
Journal: J Antimicrob Chemother Date: 1983-01 Impact factor: 5.790

6. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.

Authors: G J Cuchural; F P Tally; N V Jacobus; S L Gorbach; K Aldridge; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe
Journal: Antimicrob Agents Chemother Date: 1984-08 Impact factor: 5.191

7. Cefotetan: in-vitro antibacterial activity and susceptibility to beta-lactamases.

Authors: I Phillips; A King; K Shannon; C Warren
Journal: J Antimicrob Chemother Date: 1983-01 Impact factor: 5.790

8. In vitro activity of cefbuperazone against anaerobic bacteria.

Authors: H Wexler; W T Carter; B H Harris; S M Finegold
Journal: Antimicrob Agents Chemother Date: 1985-04 Impact factor: 5.191

9. Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species.

Authors: K E Aldridge; C V Sanders; A Janney; S Faro; R L Marier
Journal: Antimicrob Agents Chemother Date: 1984-09 Impact factor: 5.191

6. Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

Authors: M J Gribble
Journal: CMAJ Date: 1994-09-01 Impact factor: 8.262

7. In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.

Authors: N Kato; H Kato; Y Tanaka; K Bando; K Watanabe; K Ueno
Journal: Antimicrob Agents Chemother Date: 1993-05 Impact factor: 5.191

7 in total

In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria.

Review 1. Antimicrobial resistance in Bacteroides.

2. Pharmacokinetics of ceftizoxime.

3. Activity in vitro of cefotetan against non-sporing anaerobes: a comparative study.

4. Inhibitory activity of cefotetan and other beta-lactams against anaerobes.

5. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers.

6. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.

7. Cefotetan: in-vitro antibacterial activity and susceptibility to beta-lactamases.

8. In vitro activity of cefbuperazone against anaerobic bacteria.

9. Comparison of the activities of penicillin G and new beta-lactam antibiotics against clinical isolates of Bacteroides species.

10. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Review 1. New developments and concepts in antimicrobial therapy for intra-abdominal infections.

2. Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents.

Review 3. Susceptibility testing of anaerobic bacteria: myth, magic, or method?

4. Survey of Bacteroides fragilis group susceptibility patterns in Canada.

Review 5. Metronidazole. A therapeutic review and update.

6. Cefotetan: a second-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.

7. In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.